125 related articles for article (PubMed ID: 7591020)
1. Enhanced levels of tissue-type plasminogen activator in borderline hypertension.
Wall U; Jern C; Bergbrant A; Jern S
Hypertension; 1995 Nov; 26(5):796-800. PubMed ID: 7591020
[TBL] [Abstract][Full Text] [Related]
2. Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension.
Jern S; Wall U; Bergbrant A; Selin-Sjögren L; Jern C
Arterioscler Thromb Vasc Biol; 1997 Dec; 17(12):3376-83. PubMed ID: 9437182
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic system in normotensive subjects and hypertensive patients.
Armas-Hernández MJ; Hernández-Hernández R; Armas-Padilla MC; Sosa-Canache B; Cammarata R; Pacheco B; Guerrero-Pajuelo J; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):177-82. PubMed ID: 17414587
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden.
Eliasson M; Jansson JH; Nilsson P; Asplund K
J Hypertens; 1997 Apr; 15(4):349-56. PubMed ID: 9211169
[TBL] [Abstract][Full Text] [Related]
5. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
[TBL] [Abstract][Full Text] [Related]
7. Platelet function and fibrinolytic activity during rest and exercise in borderline hypertensive patients.
Gleerup G; Vind J; Winther K
Eur J Clin Invest; 1995 Apr; 25(4):266-70. PubMed ID: 7601202
[TBL] [Abstract][Full Text] [Related]
8. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
10. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
11. The fibrinolytic system is not impaired in older men with hypertension.
DeSouza CA; Dengel DR; Rogers MA; Cox K; Macko RF
Hypertension; 1996 May; 27(5):1053-8. PubMed ID: 8621196
[TBL] [Abstract][Full Text] [Related]
12. Elevated platelet P-selectin expression and platelet activation in high risk patients with uncontrolled severe hypertension.
Preston RA; Coffey JO; Materson BJ; Ledford M; Alonso AB
Atherosclerosis; 2007 May; 192(1):148-54. PubMed ID: 16764881
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension.
Huber K; Beckmann R; Frank H; Kneussl M; Mlczoch J; Binder BR
Am J Respir Crit Care Med; 1994 Oct; 150(4):929-33. PubMed ID: 7921465
[TBL] [Abstract][Full Text] [Related]
16. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
Stegnar M; Mavri A
Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction.
Gray RP; Patterson DL; Yudkin JS
Arterioscler Thromb; 1993 Mar; 13(3):415-20. PubMed ID: 8443145
[TBL] [Abstract][Full Text] [Related]
18. The effects of chronic smoking on the fibrinolytic potential of plasma and platelets.
Simpson AJ; Gray RS; Moore NR; Booth NA
Br J Haematol; 1997 Apr; 97(1):208-13. PubMed ID: 9136967
[TBL] [Abstract][Full Text] [Related]
19. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH
Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924
[TBL] [Abstract][Full Text] [Related]
20. Association of blood pressure with fibrinolytic potential in the Framingham offspring population.
Poli KA; Tofler GH; Larson MG; Evans JC; Sutherland PA; Lipinska I; Mittleman MA; Muller JE; D'Agostino RB; Wilson PW; Levy D
Circulation; 2000 Jan; 101(3):264-9. PubMed ID: 10645922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
